预约演示
更新于：2026-10-31
Pidilizumab
更新于：2026-10-31
概要
基本信息
药物类型 单克隆抗体 |
别名 Pidilizumab (USAN)、皮地利珠单抗、CT-011 + [2] |
靶点 |
作用方式 抑制剂 |
作用机制 PD-1抑制剂(细胞程序性死亡-1抑制剂) |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 146410L
来源: *****
Sequence Code 146421H
来源: *****
关联
16
项与 Pidilizumab 相关的临床试验NCT02653989
An International, Phase 2, Open-Label, Efficacy and Safety Study of MDV9300 in Patients With an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B-Cell Lymphoma
NCT02530125
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
NCT02077959
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
100 项与 Pidilizumab 相关的临床结果
登录后查看更多信息
100 项与 Pidilizumab 相关的转化医学
登录后查看更多信息
100 项与 Pidilizumab 相关的专利（医药）
登录后查看更多信息
12
项与 Pidilizumab 相关的文献（医药）2022-09-22JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1
Article
作者: Martins da Silva, João Hermínio ; Sartori, Geraldo Rodrigues ; Albuquerque, Aline de Oliveira ; da Silva Junior, Haroldo Cid
Pidilizumab is a monoclonal antibody tested against several types of malignancies, such as lymphoma and metastatic melanoma, showing promising results. In 2016, the FDA put Pidilizumab's clinical studies on partial hold due to emerging evidence pointing to the antibody target uncertainty. Although initial studies indicated an interaction with the PD-1 checkpoint receptor, recent updates assert that Pidilizumab binds primarily to Notch ligand DLL1. However, a detailed description of which interactions coordinate antibody-antigen complex formation is lacking. Therefore, this study uses computational tools to identify molecular interactions between Pidilizumab and its reported targets PD-1 and DLL1. A docking methodology was validated and applied to determine the binding modes between modeled Pidilizumab scFvs and the two antigens. We used Molecular Dynamics (MD) simulations to verify the complexes' stability and submitted the resulting trajectory files to MM/PBSA and Principal Component Analysis. A set of different prediction tools determined scFv interface hot-spots. Whereas docking and MD simulations revealed that the antibody fragments do not interact straightforwardly with PD-1, ten scFv hot-spots, including Met93 and Leu112, mediated the interaction with the DLL1 C2 domain. The interaction triggered a conformational selection-like effect on DLL1, allowing new hydrogen bonds on the β3-β4 interface loop. The unprecedented structural data on Pidilizumab's interactions provided novel evidence that its legitimate target is the DLL1 protein and offered structural insight on how these molecules interact, shedding light on the pathways that could be affected by the use of this essential immunobiological. Communicated by Ramaswamy H. Sarma.
2018-01-01Journal of neuro-oncology2区 · 医学
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma
2区 · 医学
Article
作者: Michal Yalon ; Abed Abu Kuidar ; Iris Fried ; Rina Dvir ; Michael Weintraub ; Myriam Weil Ben Arush ; Tal Ben Ami ; Mony Benifla ; Helen Toledano ; Alex Lossos ; Sergei Postovski
Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating antibodies have recently emerged as a highly promising treatment modality in multiple cancer types. We present results from the first study to evaluate the immune modulating antibody MDV9300 (pidilizumab) in pediatric patients with DIPG. All patients aged 3 years and older, diagnosed with DIPG between February 2014 and June 2015 in Israel, were offered to participate in the study. Enrolled patients were started on biweekly 6 mg/kg MDV9300 after radiation completion. Treatment was continued until disease progression on imaging. Patients were followed biweekly for the occurrence of neurological deficit toxicities and side effects. Secondary endpoints were event free survival and overall survival. Of 13 children diagnosed with DIPG during the study period, nine were enrolled in the study. The patients underwent radiotherapy and none had chemotherapy. A total of 83 cycles of MDV9300 (range 2-16) were applied. The main side effects were neutropenia (CTCAE grade 1-3), mild to moderate fatigue, and acute elevation of blood pressure. Four patients died within 1 year of the diagnosis, another three died within 2 years and two children are still alive nearly 30 months from diagnosis, with stable disease. The median event free survival is 9.3 months (range 6.8-24) and the median overall survival is 15.6 months (range 6.9-28). Preliminary results demonstrate that MDV9300 treatment is safe and may be effective in the treatment of children with DIPG.
2017-06-01Hematological oncology3区 · 医学
Immunotherapy in lymphoma
3区 · 医学
Review
作者: Federico Caligaris‐Cappio ; Stephen M. Ansell ; David G. Maloney
A multitude of studies have investigated why the immune system fails to develop an effective response against cancer and how to mobilize a successful immune therapeutic attack against cancer cells. Lymphomas are tumours of the immune system that develop from the cells devoted to the body defence within permissive specialized and well-vascularized tissue microenvironments, such as bone marrow and secondary lymphoid organs. Malignant lymphoid cells entail a bidirectional dialogue with a host of nonmalignant immune cells of both innate and adaptive immunity. This cross-talk not only favours malignant cell growth, survival, and drug resistance but also prevents antitumour response through resistance to cytotoxicity, compromised cytotoxic cell activity, and altered tumour-identifying ligand expression or secretion.1 Improving the understanding of the mechanisms that underlie the deficiency of an adequate antitumour immune response is now allowing manipulation of the immune system for the purpose of lymphoma eradication. The first question to address is through which mechanisms malignant cells subvert normal cells of the immune system to protect themselves from attack. A number of different mechanisms have been ascertained. As an example, diffuse large B cell lymphoma (DLBCL) cells commonly fail to express cell-surface molecules necessary for the recognition of tumour cells by immune-effector cells. This may occur because of mutations and deletions that inactivate either the β2-Microglobulin gene, thus preventing the cell-surface expression of the HLA class-I (HLA-I) complex that is necessary for recognition by cytotoxic T lymphocytes (CTL) or the CD58 gene, which encodes a molecule involved in T and natural killer cell-mediated responses.2 Lymphoma cells divert the classical activation of the innate immune system and subvert the antitumour immune response exerted by T helper (Th) cells, CTL, and macrophages. The apposition of lymphoma cells with T cells within involved tissues induces a dysfunction of the T-cell immunological synapse, the complex molecular structure that represents the site where the T-cell receptor (TCR) is triggered by the peptide–HLA complex. This dysfunction has been described initially in B-cell chronic lymphocytic leukemia (CLL) and subsequently also in follicular lymphoma (FL) and DLBCL. It is due to inhibitory ligand-induced impairment of T-cell actin dynamics and prevents the lysis of tumour cells through CTL.3 Notably malignant lymphoid cells may also secrete cytokines such as IL-12 that induce T cell "exhaustion," a reversible condition that occurs when T cells are exposed to prolonged stimulation with antigen and leads to a profound inability of T cells to respond to activation signals. Moreover, lymphomatous tissues are enriched with immune cell subsets that suppress an efficient immunological response against the tumour such as FoxP3 regulatory T cells (Tregs). Tregs suppress the proliferation and activity of both CD4+CD25– and CD8+ T cells, and their enrichment is contributed to by lymphoma cells that allow the preferential conversion of T helper cells into Tregs by proteins such as TGF-β or CCL22. A number of studies have suggested a critical role for monocyte/macrophage cells in chronic lymphoid malignancies. Their accumulation is favoured by the inflammatory microenvironment within infiltrated tissues that attracts monocytes/macrophages and cooperates with IL-10 to promote the M2 polarization of tumour associate macrophages. M2-polarized tumour associate macrophages promote tumour growth by stimulating angiogenesis and inducing an immunosuppressive Th2 response.4 A major achievement has been the understanding that the homeostasis of antigen-specific lymphocytes requires multiple different signals. Lymphocyte activation is triggered by specific antigen recognition through the TCR and costimulatory signals. Coinhibitory signals delivered through specialized receptors that function as immune checkpoints maintain self-tolerance and promote the resolution of inflammation during immune responses thereby preventing the development of autoimmunity. The molecular family of checkpoint inhibitors classically represented by the B7–CD28–CTLA-4 family has been enriched by the identification of the programmed cell death 1 (PD-1)/programmed death–ligands 1 and 2 (PD-L1 and PD-L2) immune checkpoint inhibitory receptor and ligands. The functional and biochemical properties of PD-1 are not limited to but have been best studied in T cells where PD-1, induced upon activation through the TCR and cytokine receptors, is necessary for the termination of the immune response. Programmed death–ligand 1 is constitutively expressed at low levels on both professional and nonprofessional antigen presenting cells as well as on a wide variety of nonhematopoietic cell types and its expression is also induced by proinflammatory cytokines. A key mechanism by which cancer cells limit the host immune response is the upregulation of PD-1 ligands and their ligation to PD-1 on tumour-specific CD8+ T cells. In the tumour microenvironment inflammatory mediators, among which interferon-γ produced by tumour-infiltrating T cells that are capable of recognizing tumour antigens is the most potent, can induce expression of PD-L1 and PD-L2 not only on cancer cells but also on other cell types such as macrophages, dendritic, and stromal cells. The expression of PD-1 ligands on tumour cells can have a genetic basis as best exemplified by classical Hodgkin lymphoma where chromosome 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) alterations have been shown to increase the abundance of PD-1 ligands.5 JAK2-STAT signalling further increases PD-1 ligand expression. Notably, Epstein-Barr virus (EBV) infection can increase expression of PD-1 ligands in EBV+ HL. Levels of PD-L1 expression in cancer cells are also regulated by epigenetic mechanisms. Lymphoma cells protect themselves from attack by the immune system through several different mechanisms. These observations have paved the way to the development of new therapeutic avenues of cancer immunotherapy. The use of genetically modified chimeric antigen receptor (CAR)-T-cells that overcome the mutational landscape of cancers and the blockade of immune checkpoint receptors that inhibit the immune response convincingly show that the possibility to eradicate lymphoid malignancies with immunotherapeutic approaches is more realistic than ever before. Two immune checkpoints have been targeted in lymphoma and antibodies that block signaling via these receptors have resulted in therapeutic benefit for patients. CTLA-4 is commonly expressed on T-cells after activation and specifically functions to down regulate T-cell activity through a variety of mechanisms. These mechanisms include preventing costimulation by outcompeting CD28 for its ligand B7 and also by inducing T-cell cycle arrest. Blocking CTLA-4 prevents down regulation of T-cell function and promotes the persistence and activation of intratumoural T-cells. Similarly, PD-1 is a negative regulator of T-cell activity and limits T-cell activation when stimulated by 1 of its 2 ligands, PD-L1 and PD-L2. Activation of this receptor typically down regulates T-cell activity and PD-1 is commonly expressed on activated and immunologically exhausted T-cells. Persistent stimulation via PD-1 results in an ineffective immune response and blocking signaling through PD-1 using an anti–PD-1 antibody allows for reactivation of suppressed or exhausted T-cells. Targeting these 2 immune checkpoints is therefore a rational therapeutic approach. Initial clinical studies utilized an anti–CTLA-4 antibody ipilimumab in B-cell lymphoma with a goal of enhancing antitumour T-cell responses. In an initial phase II clinical trial, 18 patients were treated and 2 responses were seen—1 patient with DLBCL had a complete response and 1 patient with FL had a partial response.6 Correlative studies showed that T-cell proliferation in response to recall antigens increased in most patients confirming activation of the immune system. Subsequent clinical trials were done using ipilimumab in patients with relapsed hematological malignancies post allogeneic stem cell transplant. In these studies, responses were seen in lymphoma patients including 2 complete responses in patients with HL and a partial response in patients with mantle cell lymphoma (MCL). Ipilimumab has subsequently been combined with nivolumab, an anti–PD-1 antibody, and the combination has shown significant clinical responses in HL. While targeting CTLA-4 has resulted in modest clinical benefit, clinical trials testing PD-1 blockade have shown significant promise in patients with lymphoma, particularly HL. Initial trials used an anti–PD-1 antibody pidilizumab, and while there is some controversy as to whether pidilizumab specifically targets PD-1, the initial trial of pidilizumab postautologous stem cell transplant did show a significant impact of this agent on progression free survival.7 A subsequent clinical trial of pidilizumab in combination with rituximab in FL showed a high complete response rate of 52% in the 32 patients treated. Additional clinical trials of other anti–PD-1 antibodies have been performed. Studies using nivolumab that targets PD-1 showed dramatic responses in patients with HL. In the initial phase I trial of nivolumab, the 23 patients in the HL cohort had an overall response rate of 87%.5 The responses seen in this trial have been durable and with longer-term follow-up, a significant proportion of patients have remained in remission. A subsequent confirmatory phase II study of nivolumab in HL patients confirmed an overall response rate of 68%.8 These responses have remained durable and with a median follow-up of 14 months, the median duration of response has not yet been reached. The response rates in other lymphomas have been lower but responses have been seen in patients with FL, DLBCL, and T-cell non-Hodgkin lymphoma.9 In general, responses in these histologies have been in the 20% to 40% range and responses have not been as durable. Similar results have been seen with pembrolizumab, a further antibody targeting interactions between PD-1 and its ligands. Data with this agent in classical HL have confirmed high response rates and good tolerability. In an initial phase I clinical trial, the overall response rate for the 31 patients treated was 58% and these responses have also been durable with longer-term follow-up.10 A subsequent phase II trial of pembrolizumab, including patients who progressed after autologous stem cell transplant as well as patients ineligible for a transplant, confirmed a high response rate of 68% with the responses varying between 64% and 74% depending on the subset analyzed. Correlative studies from the Hodgkin cohort in both the pembrolizumab and nivolumab studies have confirmed high expression of PD-1 ligands on the malignant cells and the majority of the overexpression is due to amplification or copy number gain at chromosome 9p24.1. The significant clinical results of particularly pembrolizumab and nivolumab in HL and other lymphomas have led to a plethora of combination studies. An initial study combining ipilimumab and nivolumab, so as to have dual immune checkpoint blockade, resulted in a 74% response rate in a cohort of 31 HL patients. Of note, however, responses have been significantly lower even with dual checkpoint blockade in other lymphoma histologies. Similarly, combination studies of immune checkpoint therapy with antibody drug conjugates such as brentuximab vedotin have been conducted. Recent reports of the results of combining brentuximab vedotin with nivolumab showed an overall response rate of 90% in HL patients in first relapse and 100% in patients who had progressed posttransplant. Further studies using multiple combinations in various lymphoma histologies are currently in progress. Clearly, targeting immune checkpoints is a promising approach to optimizing the antitumour immune response in both Hodgkin and non-Hodgkin lymphoma. A further option to overcome tumour resistance is to adoptively transfer large numbers of expanded or genetically reprogramed T-cells specific for a tumour expressed antigen. Approaches include the use of tumour infiltrating lymphocytes, cells transfected with TCR specific for tumour antigens in the context of the patient's HLA, or chimeric antigen receptor gene-modified T cells (CAR-T). Chimeric antigen receptor gene-modified T cells specific for the B cell lineage antigens CD19, CD20, and CD22 have shown the greatest promise in patients with acute lymphoblastic leukemia, NHL, and CLL. For NHL, the most encouraging antitumour activity has been with second-generation CAR constructs that have used a murine scFv specific for CD19 and linked to either the 41BB or CD28 costimulatory domains and a CD3zeta signaling sequence. Typically, cells are collected from the patient via leukapheresis and then either separated into subsets (CD4 and CD8 cells) or bulk lymphocytes directly stimulated through CD3 and CD28 and transfected with either a lentiviral or retroviral construct containing the CAR gene. After a 7- to 14-day period of cell growth in vitro, the cells are given back to the patient at a variety of doses, usually 2 to 4 days after the patient has received a cycle of lymphodepleting chemotherapy. Lymphodepletion appears important to allow upregulation of homeostatic regulatory cytokines (IL-7 and IL-15) that improve the expansion and persistence of the adoptively transferred cells and may provide some degree of transient tumour control. In most studies, low-dose or high-dose cyclophosphamide alone or in combination with fludarabine has been used. The CAR-T cells are a living therapy that may replicate and exponentially expand upon interaction with normal or abnormal cells expressing the target antigen. This can lead to very rapid tumour regression, including tumour lysis syndrome as well as toxicity resulting from cytokine release syndrome (CRS). Cytokine release syndrome appears to be caused by the interaction of CAR-T cells and antigen expressing tumour cells as well as interaction with the patient's immune system and release of inflammatory mediators including IL-6, TNF-alpha, and gamma interferon and manifest as fever, hypotension, capillary leak, and coagulopathy. This may require ICU-level care. For grading, see Lee et al.11 In most studies, an unexplained neurotoxicity with delirium and somnolence or even seizures and/or stroke like phenomena can occur in a subset of patients. Fortunately, even if significant, these neurotoxicities are usually fully reversible. Moderate-to-severe CRS can be treated by anti–IL-6 protein or receptor antibodies (tocilizumab or siltuximab) often in combination with a short course of dexamethasone. Tumour responses are usually quite rapid and occur in the first 1 to 2 months. Hospitalization is often required for supportive care, but approximately 30% of patients in the Seattle series were treated entirely as outpatients. Kochenderfer at the NCI has reported the longest outcomes for patients with NHL.12 This approach uses a murine scFv and a CD28 costimulatory domain that is transfected into bulk-stimulated T cells using a retroviral vector. Using this approach, cells are produced rapidly (<7 days), but may be comprised of widely variable T cell subsets. In the initial report, they treated 15 patients (9 with DLBCL, 2 indolent NHL, and 4 CLL) with 8 CR and 4 PR. In patients with DLBCL, 4/7 evaluable patients had a CR and 3 were ongoing between 9 and 22 months. The CRS and neurotoxicity was the most significant toxicity and 1 patient without known CRS had sudden death at day 16 post–CAR-T cells. Patients had extensive prior therapy, and the achievement of CR's in this population represents a significant finding. In addition, this was feasible in patients who had relapsed following allogeneic transplantation, without any apparent increase in graft-vs-host disease or graft rejection. Kite pharmaceuticals is planning to commercialize this approach (KTE-C19) in relapsed/refractory DLBCL and reported early results from the pivotal ZUMA-1 at ASH 2016.13 In 62 patients with DLBCL (n = 58) or transformed FL or PBMCL (n = 11), the overall response rate was 79% with a 52% initial CR rate to a targeted dose of 2 × 106 cells/kg after low-dose Cy/Fu conditioning. At 3 months, the ORR was 44% with a CR rate of 39%. Data have not yet been released for 6- and 9-month follow-up, but this compares favorably to historical data for patients with relapsed/refractory DLBCL (8% CR from the SCHOLAR-1 study). Grade 3 or greater CRS was observed in 18% and neurotoxicity in 34% of patients. Two patients died of related side effects. The Seattle group has taken a different approach by creating a more uniform CAR-T cell product by selecting CD4 and CD8 T cell populations and administering a CAR-T cell product containing CD4:CD8 cells in a defined 1:1 ratio in 32 patients with NHL.14 In this phase I/II trial, we observed that the dose of CAR-T cells was important as well as the type/intensity of lymphodepletion. Patients treated with Cy alone had a high incidence of immunologic rejection of the modified T cells that limited the duration of response. The addition of fludarabine decreased this immune rejection and resulted in more robust CAR-T cell expansion, which required a 1 log reduction in the administered T cell dose to limit toxicity. By using a defined ratio of cells, we were able to identify dose response and dose toxicity relationships. The overall response rate was 63% with a 33% CR rate. However, using Cy/Flu lymphodepletion the ORR was 72% with a 50% CR and with a longer duration of remission. This was correlated with greater CAR-T cell expansion and persistence. We were able to observe complete remission of disease in the blood, bone marrow, nodal and extra nodal tissues, and CNS. Severe CRS was observed in 13% and severe neurotoxicity in 28%, and 2 patients died of toxicity (both treated above the eventual MTD). Importantly, measurement of serum biomarkers 1 day after CAR-T cell infusion was correlated with the development of severe CRS or neurotoxicity suggesting an avenue for early intervention. Juno Therapeutics has developed this approach further (JCAR-17) in an ongoing multicenter phase I/II trial that also reported encouraging results at ASH 2016 with 82% OR and 73% CR in the first 11 evaluable patients with DLBCL.15 Of interest, 1 patient with a parenchymal brain lesion also responded with a CR and without CRS or CNS toxicity. At this time, it is difficult to compare these very different CAR-T cell products, but both approaches appear to be generating response rates and CR rates that are vastly superior to the current standards of care in this difficult to treat patient population (relapsed refractory DLBCL). The duration of remissions and the causes of disease relapse will be important to the field. However, this is likely just the beginning of a new treatment era because combination therapy with CAR-T cells and checkpoint inhibitors are a logical extension and clinical trials are ongoing. Stephen Ansell: Research funding from Bristol Myers Squibb and Merck. Federico Caligaris-Cappio: No relevant conflict of interest to declare. David Maloney: Research funding from Juno Therapeutics.
100 项与 Pidilizumab 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10390 | Pidilizumab | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性弥漫性大B细胞淋巴瘤 | 临床2期 | 美国 | 2016-12-01 | |
| 转移性黑色素瘤 | 临床2期 | 美国 | 2011-11-01 | |
| 转移性黑色素瘤 | 临床2期 | 以色列 | 2011-11-01 | |
| 复发性滤泡性淋巴瘤 | 临床2期 | 美国 | 2010-01-01 | |
| 纤维板层肝细胞癌 | 临床2期 | 以色列 | 2009-10-01 | |
| 慢性丙型肝炎基因型 1 | 临床2期 | 以色列 | 2009-09-01 | |
| 大肠腺癌 | 临床2期 | 美国 | 2009-05-01 | |
| 大肠腺癌 | 临床2期 | 保加利亚 | 2009-05-01 | |
| 大肠腺癌 | 临床2期 | 印度 | 2009-05-01 | |
| 大肠腺癌 | 临床2期 | 秘鲁 | 2009-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 2 | 糧醖網醖簾壓獵窪淵蓋(鏇獵齋顧鑰鹹淵淵壓憲) = 廠鬱憲蓋鑰願遞淵夢齋 觸獵鹽顧積廠鹹範積夢 (鑰夢蓋蓋衊鬱鬱襯鹽襯, 觸獵網範鏇製餘願糧簾 ~ 觸繭構網淵築襯製襯窪) 更多 | - | 2019-07-10 | |||
临床2期 | 7 | (Arm A) | 鹽襯憲廠夢遞鑰鏇艱繭(壓齋簾淵醖壓鏇製築範) = 遞淵範顧獵夢鏇積遞廠 窪夢鏇獵築積蓋積鏇襯 (製築廠網夢繭簾鬱壓構, 壓壓壓鏇襯鏇蓋獵顧顧 ~ 淵淵選獵餘鬱範糧願鹽) 更多 | - | 2019-07-10 | ||
鹽襯憲廠夢遞鑰鏇艱繭(壓齋簾淵醖壓鏇製築範) = 憲齋築簾製鑰鹹製衊獵 窪夢鏇獵築積蓋積鏇襯 (製築廠網夢繭簾鬱壓構, 顧壓壓夢艱廠憲網淵顧 ~ 願範簾築窪願餘範鏇醖) 更多 | |||||||
临床2期 | 4 | Laboratory Biomarker Analysis+Pidilizumab | 構築積餘艱襯憲構廠餘 = 範齋範糧觸廠簾築餘夢 襯鏇襯窪鑰醖構衊廠廠 (獵淵窪廠觸餘觸壓遞鬱, 築餘夢製築觸構廠顧遞 ~ 鹹構齋鏇膚製選鏇醖網) 更多 | - | 2018-03-19 | ||
临床2期 | 11 | (CT-011) | 願壓築願鹽蓋糧艱鑰醖 = 願襯糧築醖廠鏇鹹廠顧 簾願衊選鬱鑰獵鑰鏇獵 (網蓋顧選築壓繭衊網觸, 構憲壓襯襯築憲淵選鬱 ~ 醖鏇醖築淵範壓襯糧製) 更多 | - | 2016-11-09 | ||
DC/RCC fusion vaccine+CT-011 (CT-011 With DC/RCC Fusion Vaccine) | 顧簾獵鬱網選醖觸繭網(願鏇願憲簾鏇築顧膚蓋) = 鹹蓋鑰餘遞齋淵艱鑰壓 齋鏇廠選製齋遞鹽顧獵 (糧艱鬱獵糧範廠積願鏇, 鏇繭築艱積鑰衊夢構遞 ~ 襯選廠選製蓋醖製構夢) 更多 | ||||||
临床2期 | 32 | 齋簾壓獵醖積願廠蓋遞 = 齋願觸繭製願壓鹽糧鏇 範選簾衊膚憲製壓襯壓 (積鏇廠築簾網築顧壓範, 淵艱艱鏇鹽憲構衊膚鏇 ~ 齋繭鏇築鹽構構膚顧製) 更多 | - | 2016-06-03 | |||
临床1/2期 | 6 | 齋獵繭願鹽願餘膚鏇鑰(襯糧製襯簾鬱蓋顧醖夢) = grade 3 blood pressure elevation in one patient 襯獵製衊遞製繭簾範鑰 (艱繭憲範壓壓遞襯糧憲 ) 更多 | 积极 | 2014-11-01 | |||
Bevacizumab + Pidilizumab | |||||||
临床2期 | 72 | 壓糧獵廠構夢壓襯夢齋 = 廠鏇廠遞蓋淵糧窪觸構 廠醖積醖選鹽網餘醖艱 (鏇遞製製築獵膚構餘簾, 範餘鬱觸艱壓膚艱選窪 ~ 夢鏇製範醖鹽糧艱積齋) | - | 2014-09-12 | |||
临床2期 | 103 | 齋製積蓋範壓構願餘廠(製鹽顧範選遞襯糧選襯) = 21% 遞積選餘膚膚艱選鏇網 (遞鑰壓糧築鏇鏇遞製醖 ) 更多 | - | 2014-05-20 | |||
临床2期 | 32 | 繭鑰壓齋齋鬱製簾鏇襯(獵蓋簾選膚襯範繭衊艱) = 積鹹餘齋鑰廠壓築築壓 網選艱膚築網窪餘蓋憲 (齋廠憲構鑰窪糧膚顧襯 ) | - | 2014-01-01 | |||
临床2期 | - | 齋醖繭艱顧憲鑰膚醖鹹(蓋鏇糧築鏇淵襯遞積淵) = 簾遞網觸鏇膚鬱醖糧獵 齋夢鏇願願繭襯窪淵襯 (繭糧窪積構壓鹹淵夢齋 ) | 积极 | 2013-11-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用